Geoffrey Shouse, D.O., Ph.D.
“Dr. Shouse is a very special doctor. He listened attentively to my concerns, and he treated me with kindness and patience.”
— Patient
Dr. Shouse focuses his research on the efficacy and toxicity of cellular therapies for lymphoma. He is an active member of the Division of Lymphoma, the immune effector cell modality team and the Clinical Cellular Immunotherapy Committee. In addition, he is the principal investigator on several trials in lymphoma, bringing novel cellular and molecularly targeted therapies to patients.
He cares deeply about his patients and has become an essential member of City of Hope's team.
2007-2012, Ph.D., Osteopathic Medicine, Western University of Health Sciences, Pomona, CA
2003-2009, Ph.D., Cell, Molecular, and Developmental Biology, University of California Riverside, Riverside, CA
1998-2002, B.S., Biology, University of California Riverside, Riverside, CA
2019, Fellowship in Bone Marrow Transplantation, City of Hope, Duarte, CA
2015-2018, Fellowship in Hematology and Medical Oncology, Loma Linda University Medical Center, Loma Linda, CA
2006-2012, Postdoctoral Fellow, Cell, Molecular and Developmental
Biology, Department of Biochemistry, University of California Riverside, Riverside, CA
2012-2015, Internal Medicine, Loma Linda University Medical Center, Loma Linda, CA
2020-present, Assistant Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2018, Assistant Professor of Medicine, Division of Hematology and Oncology, Loma Linda University Medical Center, Loma Linda, CA
Dr. Shouse is currently the principal investigator of several clinical trials evaluating cellular therapies and other novel agents for treating relapsed or refractory non-Hodgkin lymphoma, including collaborative multicenter investigator-initiated trials and sponsored multicenter trials.
2021, Department of Hematology Pilot Project Grant, City of Hope, Department of Hematology & Hematopoietic Cell Transplantation, Duarte, CA
2021, CARinG Pilot Grant Award, Cancer and Aging Research Group, Duarte, CA
2021, Clinical Research Training Institute, American Society of Hematology, La Jolla, CA
2018, First Place Resident and Fellows Poster, Loma Linda University Medical Center, Loma Linda, CA
2015, Evidence-Based Medicine Award, Internal Medicine Residency, Loma Linda University Medical Center, Loma Linda, CA
2015, Research Award, Internal Medicine Residency, Loma Linda University Medical Center, Loma Linda, CA
2015, First Place Resident and Fellows Poster, Annual Postgraduate Conference, Loma Linda University Medical Center, Loma Linda, CA
2014, Abstract Achievement Award, ASH Annual Meeting, American Society of Hematology
2013-2015, Research Scholar, Internal Medicine Residency, Loma Linda University Medical Center, Loma Linda, CA
2013, Third Place Resident Poster Presentation, ACP Regional Meeting, American College of Physicians
2013, Best Resident Poster Presentation, SGIM Regional Meeting, Society of General Internal Medicine
2011, STARS Research Award, STARS Symposium, Western University of Health Sciences, Pomona, CA
2007, Research Award, CMDB Research Symposium, University of California Riverside, Riverside, CA
2005, Outstanding Teaching Assistant, Graduate Program in CMDB, University of California Riverside, Riverside, CA
2003-2004, Graduate Division Fellowship, Graduate Program in CMDB, University of California Riverside, Riverside, CA
1998-2002, Dean's Honor List, Undergraduate Award, University of California Riverside, Riverside, CA
2019-present, American Society of Transplantation and Cellular Therapy
2017-present, American Society of Hematology
2015-present American Society of Clinical Oncology
2012-present, American College of Physicians
2012-present, Society of General Internal Medicine
2007-present, American Osteopathic Association
2007-present, American Medical Association
-
Shouse G, Cao T, et al. Incidence and Causes of Prolonged Hematologic Toxicity after Chimeric Antigen Receptor T Cell Therapy: A City of Hope (COH) Experience. Blood (2020) 136 (Supplement 1): 40–41.
-
Dandapani S, Shouse G, et al. Bridging Radiation Is an Effective Strategy to Control Lymphoma in Preparation for CAR-T: A City of Hope Experience. Blood (2020) 136 (Supplement 1): 21–22.
-
Shouse G, Dulan S, et al. Real World Evaluation of Deviation Outcomes in an Immune Effector Cell Quality Program. Blood (2020) 136 (Supplement 1): 10.
-
Alderuccio J, Beaven A, Shouse G, et al. Frontline Bendamustine and Rituximab in Extranodal Marginal Zone Lymphoma: An International Analysis. Blood (2020) 136 (Supplement 1): 2–3.
-
Epperla N, Zhao Q, … Herrera A, Shouse G. Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study. Blood (2020) 136 (Supplement 1): 35-36.
-
Shouse G, Nikolaenko L. Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders. Curr Hematol Malig Rep (2019) DOI:10.1007/s11899-019-00545-5.
-
Shouse G, Merryman RW, Castagna L, et. al. Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1)/Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort. Blood (2019) 134 (Supplement_1): 775.
-
Aldoss I, Zhang J, Pillai R, Shouse G, Sanchez JF, Mei M, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V. Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia. BJH. 2019, 187, e33-54.
-
Shouse GP, Xue T, Herrera A, Siddiqi T, Zain J, Popplewell L, Forman S, Budde E. MDS as a cause for prolonged hematologic toxicity after treatment with CD19 targeted CAR-T cell therapy in patients with relapsed refractory lymphoma [Abstract]. Immunotherapy; 2019 June 18-22.
- Shouse GP, Thinn M. A Case Report of Non Germinal Center B Cell Type Diffuse Large B Cell Lymphoma Treated to Complete Response with Rituximab and lbrutinib. Case Reports in Hematology (2018). Article ID 5471368.
- Oregel KZ, Shouse GP, Oster C, Martinez F, Wang J, Rosenzweig M, Deisch J, Chen CS, Nagaraj G. An Atypical Presentation of Gelsolin Amyloidosis in a Male of African Descent with a Novel Mutation in the Gelsolin Gene. American Journal of Case Reports (2018) 30(19):374-381.
- Shouse G, Hardin S. A Case for Patient Ownership. Ars Medica (2017) 12(1):15-20.
- Shouse GP, Campion RN, Mirshahidi S, Liu X,Chen CS. Novel B55a-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest. Oncotarget (2016) 7:61081-61092.
- Campion RN, Shouse GP, Zhou Q, Mirshahidi S, Chen CS. Aberrant splicing and drug resistance in AML. Journal of Hematology and Oncology (2016) 9(85).
- Nobumori Y, Shouse G, Lee K, Shen B, Liu X. Characterization of B56 tumor-associated mutations reveals mechanisms for B56-PP2A tumor suppressor activity. Molecular Cancer Research (2013) 11(9):995-1003.
- Nobumori Y, Shouse G, Fan L, Liu X. HEAT-repeat 1 is required for B56gamma-PP2A holoenzyme assembly and tumor suppressive function. JBC (2012) 287:11030-11036.
- Shouse G, Nobumori Y, Liu X. ATM-mediated phosphorylation stabilizes B56gamma and activates the tumor suppressive function of PP2A. Oncogene (2011) 30(35):3755-65.
- Shouse G, Nobumori Y, Liu X. A B56gamma mutation in lung cancer disrupts the p53-dependent tumorsuppressor function of protein phosphatase 2A. Oncogene (2010) 29(27):3933-41.
- Shouse G, Cai X, Liu X. Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A. Mol Cell Biol. (2008) 28(1):448-56.
- Li H-H *, Cai X *, Shouse GP*, Piluso L, Liu X. A specific PP2A regulatory subunit, B56y, mediates DNA damage-induced dephosphorylation of p53 at Thr55. The EMBO Journal (2Q07) 26, 402-411. * Equal Contribution.